Lmr Partners LLP Novo Cure LTD Transaction History

Lmr Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.42 - $17.29 $190,945 - $265,816	15,374 New	15,374 $240,000
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $222,805 - $584,260	13,796 New	13,796 $222,000
Q4 2022 Feb 14, 2023	BUY	$63.98 - $85.37 $171,722 - $229,133	2,684 Added 2.52%	109,393 $8.02 Million
Q3 2022 Nov 14, 2022	SELL	$67.99 - $89.57 $188,672 - $248,556	-2,775 Reduced 2.53%	106,709 $8.11 Million
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $6.2 Million - $9.84 Million	109,484 New	109,484 $7.61 Million
Q3 2020 Nov 16, 2020	SELL	$58.05 - $111.31 $1.1 Million - $2.11 Million	-18,921 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$57.2 - $74.41 $1.08 Million - $1.41 Million	18,921 New	18,921 $1.12 Million
Q4 2019 Feb 14, 2020	SELL	$68.3 - $93.8 $1.74 Million - $2.39 Million	-25,522 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$61.86 - $97.8 $1.58 Million - $2.5 Million	25,522 New	25,522 $1.91 Million

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.86B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.